DHODH-IN-33

DHODH-IN-33 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with potent activity against A549 (IC50 = 5.22 μM) and 5637 (IC50 = 3.03 μM) . DHODH-IN-33 induces autophagy-dependent ferroptosis (mitochondrial dysfunction, lipid peroxidation, and ROS accumulation) with no notable toxicity in vivo. DHODH-IN-33 exerts anti-cancer effect by promoting the autophagy-dependent degradation of DHODH. DHODH-IN-33 can be used for non-small cell lung cancer and bladder cancer[1].

Product Specifications

CAS Number

[3026839-88-0]

UNSPSC

12352005

Target

Autophagy; Ferroptosis; ROS Kinase

Related Pathways

Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

COC1=CC2=C(N(C3C4=CC=CC=C4OC3C2)S(=O)(C5=CC=C(C=C5)C)=O)C=C1

Molecular Formula

C23H21NO4S

Molecular Weight

407.48

References & Citations

[1]Liu CY, et al. Tetrahydrobenzofuro[3,2-b]quinoline: A dual-acting autophagy-dependent DHODH inhibitor that provokes ferroptosis in lung cancer cells. Bioorg Chem. 2025 Dec;167:109203.